Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,025 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06479759RecruitingPhase 2
LM-108 with sintilimab for advanced lung cancer
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06371482RecruitingPhase 2
Durvalumab plus chemoradiation for limited-stage small cell lung cancer
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Shijiazhuang, HebeiAges 18–75 - NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT06107374RecruitingPhase 2
New imaging for immunotherapy in advanced lung cancer
This trial tests a special imaging scan called [18F]-FARAG to see how well it shows the activity of immunotherapy in advanced NSCLC. The goal is to help doctors understand if the treatment is working earlier than standard scans.
Iowa City, IowaAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT05429463RecruitingPhase 3
Surgery-ready lung cancer treatment with immunotherapy plus chemo
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hangzhou, ZhejiangAges 18–75 - NCT06491862Recruiting
Lung cancer care after chemo in Brazil
This study looks at how doctors in Brazil treat non-squamous non-small cell lung cancer after platinum chemotherapy stops working. It aims to understand real-world outcomes and help improve future care.
Belo Horizonte, Minas GeraisAges 18 years+ - NCT06348797RecruitingPhase 1
CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Chengdu, SichuanAges 18–70 - NCT07560111RecruitingPhase 2
GC101 cell therapy for advanced lung cancer
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
ShanghaiAges 18–70 - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT07748325RecruitingPhase 2
Checking if immunotherapy after surgery helps prevent lung cancer return
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Chengdu, SichuanAges 18–75 - NCT06923774Recruiting
Registry study for lung biopsy with Ion system
This study collects information from patients having a lung biopsy or nodule localization using the Ion endoluminal system. It aims to understand how well the system works in real-world settings.
Le Plessis-RobinsonAges 18 years+ - NCT07402343RecruitingPhase 2
Tarlatamab for small cell lung cancer brain metastases
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
AmsterdamAges 18 years+ - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT07459634RecruitingPhase 2
Lurbinectedin with durvalumab for extensive-stage small cell lung cancer
This trial tests a new combination of two drugs, lurbinectedin and durvalumab, for people with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard platinum-based chemotherapy along with durvalumab. The goal is to see if this combination can help control the cancer further.
Los Angeles, CaliforniaAges 18 years+ - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT03120481Recruiting
Check how respiratory health changes in people without lung problems
This trial enrolls adults who recently had a chest X-ray as part of routine health screening and did not show major abnormal findings, and who do not have significant breathing symptoms. It may help researchers understand changes in respiratory health over time and improve how respiratory disease risk is monitored.
Seoul, SeoulAges 19–90 - NCT03623958Recruiting
Image-guided minimally invasive lung surgery versus standard surgery
This study compares an image-guided version of a minimally invasive lung surgery to the standard approach for removing small lung nodules. It may help doctors improve planning and targeting of the nodule during surgery.
Boston, MassachusettsAges 18 years+ - NCT03769129Recruiting
Pembrolizumab plus lung ablation for advanced lung cancer
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT03791034Recruiting
Blood DNA test to guide treatment in early lung cancer
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
SeoulAges 18–90
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,025 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.